The availability of a good quality compound collection and library design expertise is an essential feature for the drug discovery DMTA cycle. At Jubilant Biosys, our expertise includes catering to different aspects of Compound Library Design (CLD) for developing project-specific libraries for screening in relevant biological assays or through Virtual screening. These libraries feature chemotypes enriched with diversity as well as compounds possessing desired properties and functionalities. Our strategic compilation of compound libraries ensures rapid synthesis and expediting Structure-Activity Relationship (SAR) or DMTA cycles across various discovery phases.
Compiled from https://www.jubilantbiosys.com
